Interpace Diagnostics Announces Presentation at the World Congress on Thyroid Cancer
June 13 2019 - 6:55AM
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully
integrated bioinformatics and commercial molecular diagnostic
company, today announced that Dr. Sydney D. Finkelstein,
Interpace’s Chief Scientific Officer, will present at the World
Congress on Thyroid Cancer, which is being held in Rome, Italy from
June 20-22, 2019. The presentation will detail outcomes of a study
with patients using Interpace’s ThyGenX® and ThyGeNEXT® in
combination with microRNA (miRNA) testing in indeterminate thyroid
nodules.
Session Information: Presentation
Title: Incremental value of expanded mutation panel
when used in combination with microRNA testing in indeterminate
thyroid nodules Date: June 21, 2019
Time: 1:30 pm - 3:15 pm
Room: Orsini, Level A
“I am excited to present findings from
Interpace’s thyroid study at the World Congress on Thyroid Cancer,”
stated Dr. Sydney D. Finkelstein, Interpace’s Chief Scientific
Officer. “Based on the number of participating patients, we believe
this is one of the largest and most comprehensive studies of its
kind. The trial evaluated over 8,000 patients and resulted in
important learnings for the field of analyzing thyroid nodules and
diagnosing thyroid cancer.”
The World Congress on Thyroid Cancer event is
expected to consist of more than 150 faculty and 500 delegates,
including leaders in the field of thyroid nodules and thyroid
cancer as well as Endocrinologists, Surgeons, Oncologists,
Radiologists and Nuclear Medicine Specialists. Interpace’s
presentation will be held during a non CME accreditation
session.
About Interpace Diagnostics Group
Interpace is a fully integrated commercial and
bioinformatics company that provides clinically useful molecular
diagnostic tests and pathology services for evaluating risk of
cancer by leveraging the latest technology in personalized medicine
for improved patient diagnosis and management.
Interpace’s mission is to provide personalized medicine
through molecular diagnostics, innovation and data to advance
patient care based on rigorous science. The Company currently has
four commercialized molecular tests and one test in a clinical
evaluation process (CEP); PancraGEN® for the diagnosis and
prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT®
(previously ThyGenX®) for the diagnosis of thyroid cancer from
thyroid nodules utilizing a next generation sequencing assay;
ThyraMIR® for the diagnosis of thyroid cancer from thyroid nodules
utilizing a proprietary gene expression assay; and RespriDx® that
differentiates lung cancer of primary vs. metastatic origin.
BarreGEN® for Barrett's Esophagus, is currently in a Clinical
Evaluation Program whereby we gather information from physicians
using BarreGEN® to assist us in positioning the product for full
launch, partnering and potentially supporting reimbursement with
payers. Barrett's Esophagus is a rapidly growing diagnosis that
affects over three million people in the US and over time can
progress to esophageal cancer. The Company’s data base includes
data from over 50,000 patients who have been tested using the
Company’s current products, including over 25,000 molecular tests
for thyroid nodules. Interpace has been designated by the 2018
edition of CIO Applications as one of the top 10
companies for providing bioinformatics solutions. Interpace’s
mission is to provide personalized medicine through molecular
diagnostics, innovation and data to advance patient care based on
rigorous science. For more information, please visit Interpace’s
website at www.interpacediagnostics.com.
Forward Looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, relating to the
Company’s future financial and operating performance. The Company
has attempted to identify forward looking statements by terminology
including “believes,” “estimates,” “anticipates,” “expects,”
“plans,” “projects,” “intends,” “potential,” “may,” “could,”
“might,” “will,” “should,” “approximately” or other words that
convey uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are based on current
expectations, assumptions and uncertainties involving judgments
about, among other things, future economic, competitive and market
conditions and future business decisions, all of which are
difficult or impossible to predict accurately and many of which are
beyond the Company’s control. These statements also involve known
and unknown risks, uncertainties and other factors that may cause
the Company’s actual results to be materially different from those
expressed or implied by any forward-looking statement.
Additionally, all forward-looking statements are subject to the
“Risk Factors” detailed from time to time in the Company’s most
recent Annual Report on Form 10-K, Quarterly Reports on Form
10-Q and other SEC filings. Because of these and other risks,
uncertainties and assumptions, undue reliance should not be placed
on these forward-looking statements. In addition, these statements
speak only as of the date of this press release and, except as may
be required by law, the Company undertakes no obligation to revise
or update publicly any forward-looking statements for any
reason.
CONTACTS: Investor Relations Joseph GreenEdison
Group jgreen@edisongroup.com
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Sep 2023 to Sep 2024